New immune drug STK-012 takes on tough lung cancers
Disease control
Recruiting now
This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …
Phase: PHASE1, PHASE2 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC